NEW YORK ─ Precision cancer diagnostics firm Epredia has been appointed a distributor of the Lunaphore Technologies LabSat Research platform, an automated tissue staining instrument for rapid immunohistochemistry and immunofluorescence, the firms said this week.
Next month, Epredia will begin distributing the product for research use in the US, United Kingdom, and Germany. Commercialization in Japan will begin next year, and Epredia will also distribute the platform there, the firms said.
Financial and other terms of the agreement were not disclosed.
The LabSat Research platform uses fast fluidic exchange microfluidic technology for rapid and uniform delivery of reagents to tissue samples, enabling accurate staining with improved protocol turnaround times, the firms said. A core element of the systems offered by Lunaphore, based in Lausanne, Switzerland, are its proprietary staining microfluidic chips that create a closed chamber and deliver reagents to tissue samples instantaneously.
Sandra Cummings, vice president of sales and marketing at Epredia, said in a statement that the LabSat Research platform complements her firm's instruments so it can "offer customers a more complete portfolio of immunohistochemistry staining solutions for research."
The distribution agreement comes in the wake of a strategic investment in Lunaphore by Tokyo-based PHC Holdings, the parent company of Epredia.